Clinical Implications
• In vitiligo, all the skin is affected.
• Modification of pigment distributions in the skin may be associated with other alterations, such as defects in the epidermal barrier.
• Stabilization of the disease, by targeting nonlesional skin, is an additional challenge for improving the benefits of treatment.
• Full-body phototherapy may stabilize the disease by inducing the differentiation of melanocytes, with consequent improvements in cell-cell adhesion.
• Counteracting extracellular and intracellular oxidative stress may contribute to reducing melanocyte detachment and disease progression.
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EDA Fibronectin in Keloids Create a Vicious Cycle of Fibrotic Tumor Formation
Rhiannon M. Kelsh 1 FN is an extracellular matrix (ECM) glycoprotein critical for embryogenesis, morphogenesis, and wound repair (Clark, 2014) . Although plasma fibronectin (FN), which is synthesized by the liver, circulates in blood as non-complexed molecules in a 1:10 ratio with fibrinogen (Greiling and Clark, 1997), little FN ECM exists in fully developed tissue (Yamada and Clark, 1996) . However, tissue injury or inflammation leads to rapid plasma FN deposition in complex with fibrin followed by so-called cell FN deposition by tissue cells a few days later (Yamada and Clark, 1996 Figure 1 ). Both plasma and cell FN are polymerized into fibrils and deposited into the ECM of most tissues. Most of the secondary structure of FN is organized into individually folded domains based on amino acid homology (Petersen et al., 1983) . These domains, termed Type I, II, and III, also represent biologically sites that participate in the formation of matrix fibrils and provide binding sites for cells, other matrix molecules, and growth factors (Schwarzbauer and DeSimone, 2011; Zhu and Clark, 2014) . As FN is extremely sensitive to proteolysis, FN must be deposited continuously from blood or from in situ tissue cell production to sustain its presence (Deno et al., 1983) . With healing of a wound or resolution of inflammation, both plasma FN and cell FN disappear rapidly from the tissue (Welch et al., 1990 ).
Here we focus on FN containing EDA (EDA FN) that has been found to persist in sites of skin fibrosis (Bhattacharyya et al., 2014) and in keloids, as reported in this issue (Andrews et al., 2015) .
EDA FN inductive pathways
During embryonic development, the EDA domain of FN is highly expressed. However, its expression is transient as it disappears with the increasing age of an organism (Vartio et al., 1987; Pagani et al., 1991) . In fact, the EDA domain of FN is largely absent from normal, adult tissue (Oyama et al., 1989) . It becomes upregulated, however, under specific circumstances of tissue remodeling, such as during wound repair, tissue injury, inflammation, and fibrosis (ffrench- Constant et al., 1989; Peters et al., 1989; Satoi et al., 2000; Singh et al., 2004; Muro et al., 2008) . The mechanisms that trigger upregulation of the EDA FN isoform are both cell type specific and context dependent, making it critical to understand the regulation of this process in response to extracellular signals. The molecular mechanism controlling alternative mRNA splicing of the EDA exon depends on spliceosome assembly and RNA secondary structure, as well as the serine/arginine (SR)-rich family of proteins (Lavigueur et al., 1993; Mermoud et al., 1994 Cramer et al., 1997 Buratti and Baralle, 2004) . Growth factors, stress signals, ECM proteins, cytokines, and stiffness have all been connected upstream of these SR proteins, ultimately leading to increased EDA FN expression (Naro and Sette, 2013). Over two decades ago, transforming growth factor-β (TGF-β) was first identified as a modulator of the EDA isoform levels in fibroblasts, resulting in an increased ratio of EDA to total FN (Balza et al., 1988; Borsi et al., 1990; reviewed in Leask and Abraham (2004) ). Differential cell type-specific signaling axes downstream of TGF-β have also been identified in the regulation of EDA FN splicing. In mouse embryonic fibroblasts, it was shown that activation of the PI3K/AKT/ mTOR signaling pathway facilitates phosphorylation and activation of the splicing factor SF2/ASF (also known as SRSF1), resulting in the increased expression of EDA FN. It was proposed that the modulation of AKT activity was a direct result of TGF-β-induced downregulation of PTEN (White et al., 2010) . These studies suggest that TGF-β family members can control EDA levels by altering activity and/or expression levels of splicing factors.
In addition to TGF-β, growth factors, such as HGF and EGF, as well as stress signals, have been implicated in regulating increased levels of EDA FN (Inoue et al., 1999) . Interestingly, it is known that HGF works through the PI3K cascade to increase levels of EDA FN (Magnuson et al., 1991; Seebacher et al., 1988; Blaustein et al., 2004) , further implicating this signaling pathway in regulating alternative splicing of FN. Recent evidence suggests that cell-ECM interactions will alter levels of EDA FN. Srebrow et al. (2002) demonstrated that a laminin-rich basement membrane can modulate the alternative splicing of EDA. Treatment of fibroblasts with type III and V collagens promoted the splicing and increased assembly of EDA FN (Zoppi et al., 2012) . Furthermore, the EDA domain itself has recently been implicated in promoting FN synthesis and fibrillogenesis by dermal fibroblasts (Shinde et al., 2015) . Further studies designed to understand the molecular EDA has also recently received attention due to its contribution to pathological inflammation. The major receptor believed to mediate EDA's role in inflammation is the innate immune receptor, toll-like receptor 4 (TLR-4). EDA FN has been shown to activate inflammatory pathways in dermal fibroblasts, mast cells, cytotoxic T Cells, and monocytes via TLR-4 (Okamura et al., 2002; Gondokaryono et al., 2007; Lasarte et al., 2007; McFadden et al., 2011; Kelsh et al., 2014) .
Understanding the molecular pathways involving the expression of EDA fibronectin and its ability to enhance stimulation of those pathways--i.e., a positive feedback loop--it is hoped that new, more effective treatment of keloids can break this vicious cycle.
Other receptors, in addition to TLR-4, have been identified for the EDA domain of FN: integrins α4β1, α9β1, and α4β7 (Liao et al., 2002; Shinde et al., 2008; Kohan et al., 2010) . The role of these receptors in EDA-mediated fibrosis and inflammation is still somewhat uncertain. EDA FN was shown to work through α4β1 to promote a contractile phenotype in human dermal fibroblasts (Shinde et al., 2015) . EDA has also been shown to mediate TGF-β-dependent myofibroblast differentiation and collagen synthesis via the α4β7-dependent activation of the MAPK/ ERK1/2 pathway. Integrin α9β1 has also been shown to regulate PI3K/AKT and ERK1/2 activation in response to EDA FN, ultimately leading to epithelial-mesenchymal transition in lung cancer cells (Sun et al., 2014) . The role of each of these receptors in the progression of fibrotic disease remains an important question.
Wound repair of full-thickness skin injury ideally ends after a few months with a flat, non-tender scar that is~70% as strong as normal skin (Gurtner et al., 2011) . Hypertrophic scars and keloids, however, sometimes intervene. These two abnormal responses to wound repair have fundamentally different clinical and histological appearances and distinct clinical outcomes. Hypertrophic scars do not invade, but rather generate tensile stress, on the surrounding tissue, whereas keloids do the opposite (Bolognia et al., 2012) . Given these facts it is not surprising that hypertrophic scar fibroblasts, but not keloid fibroblasts, express α-smooth muscle actin, indicative of a myofibroblast phenotype that can generate substantial tensile forces on surrounding ECM (Ehrlich et al., 1994) . In contrast, keloid fibroblasts demonstrate a greater propensity to proliferate in serum-free medium (Russell et al., 1988) , resist cell apoptosis (Chodon et al., 2000) , and have increased sensitivity to TGF-β, which induces synthesis and deposition of ECM molecules including FN and collagen (Babu et al., 1992; Bettinger et al., 1996) . In fact, TGF-β1 and β2, the TGF-β isoforms related to increased fibroblast ECM production and tissue fibrosis, are increased in keloid fibroblasts compared with normal fibroblasts and are thought to be largely responsible for fibroblasts' aggressive fibroproliferative nature in keloids (Xia et al., 2004) . Furthermore, TGF-β1 and β2 also increase the expression of EDA FN (Viedt et al., 1995) and thus may be responsible for the increased EDA FN observed in keloids (Andrews et al., 2015) . Interestingly, EDA FN stimulates TLR-4 signaling (Bhattacharyya et al., 2014) that in turn augments TGF-β responses (Bhattacharyya et al., 2013) . Thus, keloids may arise from a feedforward mechanism in which EDA-FN stimulates both TLR-4 and integrins to augment TGF-β-driven fibroblast activation and ECM deposition including collagen and more EDA FN (Figure 2 ).
EDA FN and keloids
Although it has been known for some time that TGF-β1 and β2 act through connective tissue growth factor (Colwell et al., 2005) , more recently it has been found that β-catenin signaling is required for TGF-β-mediated fibrosis (Akhmetshina et al., 2012), which helps explain why it was previously found that active TGF-β alone was insufficient to induce skin fibrosis (Campaner et al., 2006 
